Jennifer Doudna presents brief history of CRISPR-Cas9 biology, recent results, and its use for targeted cell-based therapy.
An invited talk in the Precision Medicine: Data and Discovery for Improved Health and Therapy Session
Jennifer Doudna, Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences
Howard Hughes Medical Institute Investigator, and Professor, Molecular & Cell Biology; Professor, Chemistry at UC Berkeley
31 янв 2016